Device maker r4 Vascular will this week begin selling a new catheter that features a novel coating designed to prevent clotting. The Duraspan catheter is intended for use by patients undergoing ...
DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...
Please provide your email address to receive an email when new articles are posted on . Researchers confirmed three early exit site signs and symptoms of catheter infection: pain, hyperemia/redness ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
Please provide your email address to receive an email when new articles are posted on . Using data from the US Renal Data System, researchers identified 74,194 Medicare-eligible patients who initiated ...
TAMPA, Fla.—Tenecteplase, a thrombolytic agent, may significantly improve the function of hemodialysis (HD) catheters blocked by blood clots, according to data from a phase 3 open-label trial. “It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results